CAMBRIDGE, Mass., July 30, 2020 /PRNewswire/ -- Synlogic, Inc.
(Nasdaq: SYBX), a clinical stage company bringing the
transformative potential of synthetic biology to medicine, today
announced the promotion of Antoine 'Tony' Awad to the position of
Chief Operating Officer. As Chief Operating Officer, Tony will
drive Synlogic's end to end development & manufacturing
organization and supply chain as well as have broader corporate
operations responsibilities, inclusive of laboratory operations, IT
infrastructure, and the quality organization.
"At Synlogic, we are executing on our mission to bring the
transformative potential of synthetic biology to medicine and
continue to grow our leadership team to advance that mission," said
Aoife Brennan, M.B. Ch.B.,
Synlogic's president and chief executive officer. "Tony's
leadership has been instrumental in realizing a critical component
of that mission – bringing Synthetic Biotic medicines from lab to
the clinic and paving the way for potential future
commercialization. This expanded role is both a recognition of his
impact on Synlogic and a signal of the criticality of manufacturing
capabilities to our future success."
"Thank you to Aoife and Synlogic for the trust and teamwork over
the past two years," said Tony Awad,
Synlogic's chief operating officer. "I am looking forward to
continuing to advance the Synthetic Biotic platform and potentially
providing new treatment options to patients with PKU, Enteric
Hyperoxaluria, and other devastating diseases."
Tony joined Synlogic in December
2018 as Head of Technical Operations. He brings over 15
years of experience in the biotechnology and pharmaceutical
industry with substantial experience in the development and
manufacturing of novel therapeutics from pre-IND studies through
global commercialization. Prior to joining Synlogic, Tony served as
Senior Vice President of CMC and Operations at Abpro Therapeutics
and L.E.A.F. Pharmaceuticals and served in roles of increasing
responsibility at Ipsen Biosciences and Merrimack Pharmaceuticals.
Tony is a graduate of Boston University
and holds degree in biochemistry and molecular biology and
conducted graduate research at Boston
University School of Dental Medicine.
Synlogic also announced the appointment of Andrew Marsh as Head of Development Operations.
Andrew brings over 15 years of experience across an array of
therapeutic areas, including rare diseases and oncology, and has
executed initial IND through registrational human clinical
studies.
Prior to joining Synlogic he served as Ra Pharmaceuticals' Head
of Clinical Development. Andrew is a graduate of Boston University and holds a degree in biomedical
engineering. He will be responsible for Clinical Operations,
Biometrics, and Clinical Bioanalytics, and will drive execution of
clinical studies of Synthetic Biotic medicines, including SYNB1618
for the potential treatment of PKU, SYNB8802 for the potential
treatment of enteric hyperoxaluria, and SYNB1891 for the potential
treatment of solid tumors in combination with checkpoint
inhibitors.
About Synlogic
Synlogic™ is bringing the
transformative potential of synthetic biology to medicine. With a
premiere synthetic biology platform that leverages a reproducible,
modular approach to microbial engineering, Synlogic designs
Synthetic Biotic medicines that target validated underlying biology
to treat disease in new ways. Synlogic's proprietary pipeline
includes Synthetic Biotics for the treatment of metabolic disorders
including Phenylketonuria (PKU) and Enteric Hyperoxaluria (HOX).
The company is also building a portfolio of partner-able assets in
immunology and oncology.
Forward-Looking Statements
This press release contains
"forward-looking statements" that involve substantial risks and
uncertainties for purposes of the safe harbor provided by the
Private Securities Litigation Reform Act of 1995. All statements,
other than statements of historical facts, included in this press
release regarding strategy, future operations, clinical development
plans, future financial position, future revenue, projected
expenses, prospects, plans and objectives of management are
forward-looking statements. In addition, when or if used in this
press release, the words "may," "could," "should," "anticipate,"
"believe," "estimate," "expect," "intend," "plan," "predict" and
similar expressions and their variants, as they relate to Synlogic
may identify forward-looking statements. Examples of
forward-looking statements, include, but are not limited to,
statements regarding the potential of Synlogic's platform to
develop therapeutics to address a wide range of diseases including:
cancer, inborn errors of metabolism, and inflammatory and
immune disorders; the future clinical development of Synthetic
Biotic medicines; the approach Synlogic is taking to discover and
develop novel therapeutics using synthetic biology; the expected
timing of Synlogic's clinical trials and availability of clinical
trial data; the timing and progress of our Phase 1 clinical trial
of SYNB1891 in patients with advanced solid tumors or lymphoma; and
the potential benefits of SYNB1891. Actual results could differ
materially from those contained in any forward-looking statement as
a result of various factors, including: the uncertainties inherent
in the clinical and preclinical development process; the ability
of Synlogic to protect its intellectual property rights;
and legislative, regulatory, political and economic developments,
as well as those risks identified under the heading "Risk Factors"
in Synlogic's filings with the SEC. The
forward-looking statements contained in this press release
reflect Synlogic's current views with respect to future
events. Synlogic anticipates that subsequent events and
developments will cause its views to change. However,
while Synlogic may elect to update these forward-looking
statements in the future, Synlogic specifically disclaims
any obligation to do so. These forward-looking statements should
not be relied upon as representing Synlogic's view as of any date
subsequent to the date hereof.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/synlogic-announces-promotion-of-antoine-tony-awad-to-chief-operating-officer-and-additions-to-leadership-team-301102169.html
SOURCE Synlogic, Inc.